检索问题
干细胞疗法可以治疗哪些疾病？相关临床研究进展
干细胞疗法是一种具有再生医学潜力的治疗手段，通过提供受损或病变组织的健康细胞以促进修复。这项技术近年来在多个领域显示了希望，并正在不断发展。根据现有的文献和临床研究，干细胞疗法目前可被应用于多种疾病，包括但不限于眼病、肺纤维化、肾脏疾病、儿童疾病以及与COVID-19相关的病症。
眼科疾病
根据一项关于眼科疾病的干细胞疗法的研究，干细胞治疗的安全性、有效性以及其伦理和监管标准得到了梳理。研究表明，干细胞的特性与其在眼病治疗中的应用密切相关，带来了快速发展的潜力。例如，治疗角膜失明和视网膜疾病的方法正在不断探索中，这些干细胞疗法的临床研究正在进行中。此领域的挑战包括技术难度和长期可能产生的并发症，因此干细胞的应用需在严格的临床试验框架内进行。
肺纤维化
在肺纤维化的治疗中，间充质干细胞(MSC)也显示出了良好的应用前景。现有的研究通常集中在细胞疗法在小鼠模型中的表现，尤其是对于肺组织修复和再生的机制。有一些临床试验正在进行，尽管现在的研究数量较少，但初步结果表明MSC可以在调节组织重塑和免疫反应中发挥作用。这表明干细胞在胸腔疾病方面可能是一个有效的治疗选项。
儿童疾病
近年来，儿童疾病领域的干细胞疗法也在不断进展。研究显示，细胞疗法在儿童患者中的临床试验数量逐步增加。不同来源和类型的干细胞在不同疾病中的应用显示了多样性，特别是在一些特殊儿童疾病中的应用。例如，干细胞疗法在某些儿科疾病中改善了临床结果和生活质量，尽管仍需进一步的研究以优化治疗时间和实施方案。
肾脏疾病
在肾脏疾病方面，特别是急性肾损伤和慢性肾病中，MSC展示出了其再生和免疫调节的潜力。现有的研究显示，干细胞疗法有可能改善肾功能并减少相关并发症的发生，有希望成为这些病症的有力治疗手段。随着单细胞测序、基因编辑等先进技术的发展，结合治疗和个性化治疗的探索也在加速推进，从而增强干细胞疗法的有效性和安全性。
COVID-19 相关疾病
针对COVID-19的干细胞疗法正在受到重视，研究表明干细胞可能在修复因新型冠状病毒而受损的组织方面具有潜力。通过纳米载体技术的干细胞疗法可能为治疗肺炎及与COVID-19相关的肺部疾病提供新的思路。这样的进展可能为应对未来大流行病提供有效的治疗方案。
面临的挑战和未来方向
尽管干细胞疗法在上述多个领域显示出良好的前景，但仍然面临着诸多挑战，包括缺乏足够的临床验证、潜在的伦理问题以及治疗的标准化不足。许多研究仍处于预临床阶段，大多数干细胞治疗尚未成为临床实践的标准疗法，这需要在未来的研究中得到解决。
综上所述，干细胞疗法可以用于眼科疾病、肺纤维化、儿童疾病、肾脏疾病以及COVID-19相关病症等多个领域。相关的临床研究正在不断增多，体现了这一领域的活跃性与未来发展潜力。不过，为了实现这些干细胞疗法的广泛应用，仍需更多基于证据的临床试验和相应的伦理监管框架。
References
1The current state of stem cell therapy for ocular disease.PubMed
Samantha Bobba, Nick Di Girolamo, Megan Munsie, et al.
Herein, we review the safety, efficacy, regulatory standards and ethical implications of the use of stem cells in ocular disease. A literature review was conducted, registered clinical trials reviewed, and expert opinions sought. Guidelines and codes of conduct from international societies and professional bodies were also reviewed. Collated data is presented on current progress in the field of ocular regenerative medicine, future challenges, the clinical trial process and ethical considerations in stem cell therapy. A greater understanding of the function and location of ocular stem cells has led to rapid advances in possible therapeutic applications. However, in the context of significant technical challenges and potential long-term complications, it is imperative that stem cell practices operate within formal clinical trial frameworks. While there remains broad scope for innovation, ongoing evidence-based review of potential interventions and the development of standardized protocols are necessary to ensure patient safety and best practice in ophthalmic care.
2Stem cell therapy in pulmonary fibrosis.PubMed
Argyris Tzouvelekis, Antonis Antoniadis, Demosthenes Bouros
PURPOSE OF REVIEW: In the last years, we have witnessed an explosion in preclinical data relating to the isolation, differentiation and application of mesenchymal stem cells (MSCs) as a treatment option in animal models of lung fibrosis and inflammation. The scope of this review is to summarize current knowledge regarding the roles of MSCs in lung tissue repair and regeneration and to highlight future therapeutic perspectives and clinical applications in safety and efficacy trials. RECENT FINDINGS: Although there have been interesting studies of cell therapy for diseases of many systems, there has been a paucity of preclinical and clinical studies regarding pulmonary fibrosis. Today, we have made progress with respect to the understanding of the mechanisms of action and application of MSCs in animal models of lung fibrosis as regulators of tissue remodeling and immune response. There are only a few ongoing clinical trials involving MSCs in chronic lung diseases and extrapolation of these data to underline future therapeutic applications in patients with idiopathic pulmonary fibrosis. SUMMARY: Adult MSCs may prove to be a valuable therapeutic option in lung tissue rescue and repair based on their ready availability, immunomodulatory effects and capacity for cell differentiation.
3Innovations in cell therapy in pediatric diseases: a narrative review.PubMed
Razan El Sayed, Karan Michael Shankar, Atharwa Rajan Mankame, et al.
BACKGROUND AND OBJECTIVE: Stem cell therapy is a regenerative medicine modality that has the potential to decrease morbidity and mortality by promoting tissue regeneration or modulating the inflammatory response. An increase in the number of clinical trials investigating the efficacy and safety of stem cell therapy in pediatric diseases has led to advancements in this field. Currently, multiple sources and types of stem cells have been utilized in the treatment of pediatric diseases. This review aims to inform researchers and clinicians about preclinical and clinical stem cell therapy trials in pediatric patients. We discuss the different types of stem cells and the wide spectrum of stem cell therapy trials for pediatric diseases, with an emphasis on the outcomes and advancements in the field. METHODS: PubMed and clinicaltrials.gov databases were searched on October 28, 2022 using the following Medical Subject Headings (MeSH) terms "stem cell" or "stem cell therapy" with an age filter <18 years. Our search was limited to publications published between 2000 and 2022. KEY CONTENT AND FINDINGS: Diverse sources of stem cells have different properties and mechanisms of action, which allow tailored application of stem cells according to the pathophysiology of the disease. Advancements in stem cell therapies for pediatric diseases have led to improvements in clinical outcomes in some pediatric diseases or in quality of life, such therapies represent a potential alternative to the current treatment modalities. CONCLUSIONS: Stem cell therapy in pediatric diseases has shown promising results and outcomes. However, further studies focusing on the implementation and optimal treatment timeframe are needed. An increase in preclinical and clinical trials of stem cell therapy targeting pediatric patients is required to advance our therapeutic applications.
4Nanoconjugates-Based Stem Cell Therapy for the Management of COVID-19.PubMed
Drashti Desai, Pravin Shende
A potential ability of stem cells (SCs) is to regenerate and repair tissues in the human body by providing great prospects for therapeutic applications in the field of medicine. Currently, SC therapy is used in various conditions like diabetes, neurodegenerative disorders, etc. but faces some limitations like patient biocompatibility and chances of cross-infection. SCs are further modulated with nanoconjugates to overcome such challenges and will offer an advantage in the treatment of COVID-19. This pandemic requires design and development of proper treatment to save the life of human beings. Advancements in SC-based nanoconjugated therapy will open new avenues and create a significant impact in the development of futuristic nanomedicine. It may also emerge as a potential therapy for the management of infection in patients suffering from SARS-CoV-2 and related diseases such as pneumonia and virus-induced lung injuries. Graphical abstract Mechanisms of stem cell-based nanoconjugates for inhibition of replication of corona virus.
5Narrative Review of Mesenchymal Stem Cell Therapy in Renal Diseases: Mechanisms, Clinical Applications, and Future Directions.PubMed
Yanjun Wang, Pengli Luo, Tana Wuren
Renal diseases, particularly acute kidney injury (AKI) and chronic kidney disease (CKD), are significant global health challenges. These conditions impair kidney function and can lead to serious complications, including cardiovascular diseases, which further exacerbate the public health burden. Currently, the global AKI mortality rate is alarmingly high (20%-50%); CKD is projected to emerge as a major global health burden by 2040. Existing treatments such as hemodialysis and kidney transplantation have limited effectiveness and are often associated with adverse effects. Mesenchymal stem cells (MSCs) offer considerable potential for treating renal diseases owing to their regenerative and immunomodulatory properties. Thus, this review focuses on the application of MSCs in renal disease, discusses fundamental research findings, and evaluates their application in clinical trials. Moreover, we discuss the impact and safety of MSCs as a therapeutic option and highlight challenges and potential directions for their clinical application. We selected research articles from PubMed published within the last 5 years (from 2019), focusing on high-impact journals and clinical trial data, and included a few key studies predating 2019. Considerations included the novelty of the research, sample size, experimental design, and data reliability. With advancements in single-cell sequencing, CRISPR/Cas9 gene editing, and other cutting-edge technologies, future MSC research will explore combination therapies and personalized treatments to provide more promising, safer treatments with reduced adverse reactions and enhanced therapeutic outcomes. These advances will improve kidney disease treatment methods, enhance patient quality of life, and maximize the benefits of MSC therapies.
6[Progress and clashes in stem cell therapy research].PubMed
C L Mummery, L W van Laake
The concept of stem cell therapy, the repair of damaged or diseased tissue by transplantation of healthy cells, is deceptively simple. This simplicity has led to the hype among desperate patients, their doctors and the media: it would seem that every ailment can be treated with stem cells. At this time, however, the scientific truth is mostly disappointing. The recent claim from Korea of a major breakthrough - the ability to grow stem cells from cloned embryos - turned out to be fraudulent. With the exception ofapplications in haematologic diseases, skin wounds, and bone and cartilage diseases, most of the putative therapeutic applications of stem cell therapy are still under preclinical investigation. These include the treatment of Parkinson's and Alzheimer's disease, paraplegia, cerebral infarction, amyotrophic lateral sclerosis, multiple sclerosis and muscular dystrophy. The treatment of cardiac infarction is currently being investigated in clinical trials.